Drug Information

Drug (ID: DG01734) and It's Reported Resistant Information

Name	Bevacizumab/Erlotinib
Synonyms	Bevacizumab/Erlotinib Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Lung cancer [ICD-11: 2C25]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Aberration of the Drug's Therapeutic Target (ADTT)		Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR)			[1]
Molecule Alteration	Missense mutation	p.L858R (c.2573T>G)	Molecule Info
Sensitive Disease	Lung adenocarcinoma [ICD-11: 2C25.0]		Disease Info
Experimental Note	Identified from the Human Clinical Data

References

Ref 1	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialLancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.